Your browser doesn't support javascript.
loading
Characterization of CD177-reactive iso- and auto-antibodies.
Traum, Annalena; Hofmann, Christine; Haas, Sabine; Schmidt, Silke; Bein, Gregor; Sachs, Ulrich J; Bayat, Behnaz.
Affiliation
  • Traum A; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Hofmann C; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Haas S; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Schmidt S; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Bein G; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Sachs UJ; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
  • Bayat B; Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
Transfusion ; 61(6): 1916-1922, 2021 06.
Article in En | MEDLINE | ID: mdl-33734454
ABSTRACT

BACKGROUND:

CD177 is a surface protein on neutrophils and a main mediator for the surface expression of proteinase 3 (PR3). Its functions are largely unknown. At least three types of antibodies have been described to target CD177 isoantibodies, which are formed in CD177-null individuals as a result of an immune reaction following transfusion or pregnancy; autoantibodies present in sera from patients with autoimmune neutropenia; and antineutrophil cytoplasmic antibodies in sera from patients with glomerulonephritis with polyangiitis. In this study, we aimed to compare the binding characteristics of auto- and iso-antibodies to optimize their detectability in the neutrophil serology laboratory. STUDY DESIGN AND

METHODS:

The reactivity of iso- and auto-antibodies against CD177 was studied using granulocytes, "native" CD177/PR3 complex, and recombinant CD177 or PR3.

RESULTS:

All iso- and auto-antibodies were reactive with CD177/PR3 when immobilized with monoclonal antibody (moab) 7D8. Seventy-five percent of autoantibodies, but none of the isoantibodies, did not react with CD177/PR3 immobilized with moab MEM166. The majority of autoantibodies did not react with recombinant CD177, whereas most isoantibodies tested positive.

DISCUSSION:

Our results suggest that iso- and auto-antibodies against CD177 target different epitopes. Isoantibodies mainly target CD177 alone, while the majority of autoantibodies target a native epitope present on the neutrophil surface, but absent from recombinant CD177 which lacks PR3. Moab MEM166 binds to the native epitope and hinders the binding of CD177 autoantibodies. The results may help to design diagnostic strategies, especially for the identification of autoantibodies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Receptors, Cell Surface / Isoantigens Type of study: Prognostic_studies Limits: Humans Language: En Journal: Transfusion Year: 2021 Document type: Article Affiliation country: Germany Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoantibodies / Receptors, Cell Surface / Isoantigens Type of study: Prognostic_studies Limits: Humans Language: En Journal: Transfusion Year: 2021 Document type: Article Affiliation country: Germany Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA